Dermatologists Urge Greater Focus on Facial Erythema in Rosacea Patients

Facial erythema and quality of life

New developments in rosacea call for dermatologists to place greater emphasis on addressing persistent facial erythema, according to experts who took part in a recent National Rosacea Society (NRS) roundtable. The goal of the roundtable discussion was to provide an update on this key aspect of the disorder, based on the new standard classification system, recent burden-of-illness study results, new standard management options and significant advances in medical therapy and patient care.

New Studies Move Topical Minocycline Foam for Rosacea Closer To Approval

Topical Minocycline Foam for Rosacea

Two phase 3 studies of Foamix Pharmaceuticals’ FMX103 (minocycline, 1.5% foam) were published in the Journal of the American Academy of Dermatology (online January 26). Foamix conducted FX2016-11 and FX2016-12 (Studies 11 & 12) to support the New Drug Application (NDA) submission of FMX103, which is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe papulopustular rosacea in adults.

April is Rosacea Awareness Month

National Rosacea Society

The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to educate the public on this often life-disruptive disorder estimated to affect more than 16 million Americans and 415 million individuals worldwide. During April and throughout the year, the NRS will conduct public education activities to reach the many millions of rosacea sufferers who may not realize they have a medical condition that can be treated, emphasizing the warning signs and urging those who suspect they may have rosacea to see a dermatologist.

PDL Offers Long-Term Efficacy in Rosacea Patients

Cosmetic and Laser Therapy Study

Lasers and light sources are highly effective in reducing the redness and visible vessels of rosacea, but how long do these benefits last? In an effort to document both efficacy and continuity of benefits of pulsed dye laser (PDL) treatment in rosacea, researchers Emel Bulbul Baskan and Asli Akin Bell of Turkey treated 14 rosacea patients with one to four PDL sessions. They used physician clinical assessment (PCA), patient self-assessment (PSA), and erythema and telengiectasia grading scores to evaluate efficacy. The patients were then followed for 21.64+/-14.25 months.

New PDL Device Safer and More Effective for Rosacea

V-Beam Prima offers larger beam diameter

The V-Beam Prima (Syneron-Candela), a new, long-pulse, higher‐energy, 595nm pulse dye laser with dynamic spray cooling and a 15mm diameter circular treatment beam, is effective for rosacea-related redness. And the larger beam size improves both outcomes and patient safety, according to a study Eric F. Bernstein, MD, et al, published on April 10, 2018, in Lasers in Surgery and Medicine.

Obesity and Waist Circumference Risk Factors for Rosacea

Obesity and Waist Circumference Correlated with Skin Disease

Obesity is associated with an increased risk of rosacea in women, according to a new study published in the December 2017 issue of the Journal of the American Academy of Dermatology. Authors Suyun Li, PhD, et al, identified 5,249 cases of rosacea diagnosed from 1991-2005 among 89,886 women who participated in the Nurses’ Health Study II. They found significant correlation between rosacea risk and higher body mass index (≥35), particularly among those who had gained weight after age 18.